Compare Aegon Ltd. (AEG) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aegon Ltd. vs BioNano Genomics Inc — how do they compare? Aegon Ltd. trades at $8.73 (market cap $12.98B), while BioNano Genomics Inc trades at $1.14 (market cap $13.08M). The key difference: Aegon Ltd. is far larger — about 992.4× BioNano Genomics Inc's market cap, and Aegon Ltd. pays a 5.3% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| AEG | BNGO | |
|---|---|---|
Market Cap | $12.98B | $13.08M |
Sector | Financials | Health |
52-Week High | $8.79 | $4.92 |
52-Week Low | $6.79 | $1.09 |
Enterprise Value | $14.11B | $15.69M |
Dividend Yield | 5.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEG trades at $8.75, up 1.04% on the day, with a P/E of 12.86 and P/S of 0.55 indicating potential undervaluation. Recent earnings show mixed results, beating estimates in Q2 and Q3 2025 but missing in Q4. The company is undergoing strategic simplification, including moving its legal seat to Delaware and focusing on U.S. operations, supported by a dividend of $0.25 payable in July 2026. Technical indicators are bullish on moving averages but neutral on oscillators.
Outlook is cautiously optimistic with a 27.78% analyst buy rating, driven by restructuring benefits and U.S. market focus. Risks include execution challenges in the transition, volatile cash flows, and competitive pressures. The stock presents a value opportunity if the strategic pivot succeeds, but investors should monitor earnings consistency and debt management.
BNGO trades at $1.14, down 0.87% on the day, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported Q1 2026 revenue of $28.51M and a net loss of $26.40M, though it beat EPS estimates. Recent news includes leadership changes, debt retirement, and growing adoption of its optical genome mapping technology. Valuation ratios appear low with a P/E of 0.03 and P/S of 0.3, but profitability remains negative.
Outlook is cautiously optimistic due to improving cash flow trends and analyst support, but significant risks persist from ongoing losses and competitive pressures. The stock's near-term direction hinges on achieving profitability and sustaining revenue growth amid high operational costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
